Dr Reddys Laboratories Ltd Analyst Rating
based on 39 analysts
28.95%
Buy
34.21%
Hold
36.84%
Sell
Based on 39 analysts offering long term price targets for Dr Reddys Laboratories Ltd. An average target of ₹1336.87
Source: S&P Global Market Intelligence
Dr Reddys Laboratories Ltd Share analysis
Dr Reddys Laboratories Ltd price forecast by 39 analysts
Upside of10.08%
High
₹1655
Target
₹1336.87
Low
₹969
Dr Reddys Laboratories Ltd target price ₹1336.87, a slight upside of 10.08% compared to current price of ₹1214.45. According to 39 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Dr Reddys Laboratories Ltd revenue growth forecast
Expected growth rate Q1, FY2026:23.75%
Forecast
Actual
Including amortisation and stock based compensations
Dr Reddys Laboratories Ltd EPS growth forecast
EPS estimate Q1, FY2026:7.01%
Forecast
Actual
Source: S&P Global Market Intelligence
Dr Reddys Laboratories Ltd Performance
Day's Low
Day's High
₹1,193.6₹1,223.252 Week's Low
52 Week's High
₹1,074₹1,421.49
| Returns % | |
| 1 Month Return | -8.11 % |
| 3 Month Return | -12.69 % |
| 1 Year Return | + 7.58 % |
| Market Stats | |
| Previous Close | ₹1,195.35 |
| Open | ₹1,199.00 |
| Volume | 7.64L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹99,738.18Cr |
Dr Reddys Laboratories Ltd Key Statistics
| P/E Ratio | 18.94 |
| PEG Ratio | 6.64 |
| Market Cap | ₹99,738.18 Cr |
| P/B Ratio | 4.22 |
| EPS | 66.882 |
| Dividend Yield | 0.65 |
| Sector | Pharmaceuticals |
| ROE | 19.42 |
Dr Reddys Laboratories Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹99,738.18 Cr | 21.58% | 0.52 | ₹5,577 Cr | ₹28,011 Cr | |
| HOLD | ₹1,58,673.22 Cr | 48.01% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,04,979.37 Cr | 51.98% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| HOLD | ₹38,791.39 Cr | 5.64% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹29,441.13 Cr | -0.71% | 0.50 | ₹772 Cr | ₹5,664 Cr |
Dr Reddys Laboratories Ltd Mutual Fund Holdings
About Dr Reddys Laboratories Ltd
Dr Reddy's Laboratories Ltd has a diverse portfolio of products and services, including prescription drugs, generic drugs, over-the-counter drugs, active pharmaceutical ingredients, biotechnology products, and nutraceuticals. Its most popular products include antibiotics, anti-infectives, anti-diabetics, anti-cancer, cardiovascular, gastrointestinal, and dermatology products. Some of its popular brands include Omez, Ciprocin, and Revital. It also has a strong presence in the generics market with its brands such as Reditux and Reditux-D.
Share Price: ₹1214.45 per share as on 22 Nov, 2024 04:01 PM
Market Capitalisation: ₹99,738.18Cr as of today
Revenue: ₹8,016.10Cr as on September 2024 (Q3 24)
Net Profit: ₹1,341.90Cr as on September 2024 (Q3 24)
Listing date: 03 Nov, 1994
Chairperson Name: K Satish Reddy
| Organisation | Dr Reddys Laboratories Ltd |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Dr Reddys Laboratories Ltd
Dr Reddys Partners with Telangana for New Facilities - 22 Nov, 2024
Dr Reddys Laboratories, along with five leading pharmaceutical companies, has signed memorandums of understanding with the Telangana government to establish manufacturing facilities in Pharma City.
Dr Reddy's Faces Regulatory Setback, Shares Decline - 21 Nov, 2024
Dr Reddy's Laboratories shares dropped 3.2% following the USFDA's issuance of a Form 483 with seven observations from a recent inspection of its Hyderabad facility. The company reported a decline in net profit for Q2 FY25 but noted revenue growth.
USFDA Inspection at Dr Reddy's API Facility - 20 Nov, 2024
The USFDA conducted a GMP inspection at Dr Reddy's API manufacturing facility in Bollaram, Hyderabad, issuing a Form 483 with seven observations.
Dr. Reddy's Receives USFDA Observations at Hyderabad Plant - 19 Nov, 2024
Dr. Reddy's Laboratories announced it received seven observations from the USFDA following a GMP inspection at its Hyderabad API facility. The company is committed to addressing these observations promptly.
Dr. Reddy's Faces Recall and Market Decline - 18 Nov, 2024
Dr. Reddy's Laboratories faced a recall of Morphine Sulfate tablets due to manufacturing issues, leading to a 2.14% drop in shares. Additionally, Zydus announced a co-marketing agreement for a biosimilar with Dr. Reddy's, providing potential future revenue.
Dr Reddys Laboratories Issues Recall for Morphine Tablets - 17 Nov, 2024
Dr Reddys Laboratories is recalling Morphine Sulfate extended-release tablets in the US due to manufacturing issues, including failed impurities and degradation specifications. The recall affects 2,040 bottles of 15 mg and 532 bottles of 30 mg strengths.
Dr Reddy's Penalized by Mexican Drug Regulator - 14 Nov, 2024
Dr Reddys Laboratories has been fined Rs 27 lakh by Mexico's drug regulator for deviations in import filing guidelines, including invoice date errors and reference standard discrepancies.
Dr Reddy's Laboratories Positioned for Growth - 13 Nov, 2024
Dr Reddy's Laboratories, a leading Indian pharma company, is well-positioned for growth due to its strong R&D focus, diverse product portfolio, and favorable currency dynamics. The company is expected to benefit from a weaker rupee and supportive US drug pricing policies, enhancing its export potential. Financial projections indicate steady revenue and profit growth through FY24.
Dr Reddy's Aims for Top Five in Indian Pharma Market - 11 Nov, 2024
Dr Reddy's Laboratories plans to rise to the fifth position in the Indian pharma market within five years, focusing on brand planning, collaborations, innovation, and inorganic growth. The company aims for double-digit growth, leveraging its recent acquisition of Sanofi India's vaccine portfolio and exploring M&A opportunities in chronic therapies.
Dr. Reddy's Participates in Green Pharma City Review - 08 Nov, 2024
Madan Mohan Reddy and representatives from major pharma companies attended a review meeting on the Green Pharma City project in Hyderabad, led by Telangana's IT and Industries Minister.
Dr. Reddy's Releases Results and Target Price Update - 07 Nov, 2024
Dr. Reddy's Laboratories released its unaudited financial results for Q2 and H1 FY2024, maintaining FY26E estimates with a target price of INR 1,329 and an upgraded rating to HOLD.
Dr Reddy's Reports Mixed Q2 Results Amid Challenges - 06 Nov, 2024
Dr Reddy's Laboratories posted a 15% decline in net profit despite record revenues of Rs 8,016 crore. Analysts express mixed sentiments due to ongoing US market challenges and future earnings visibility concerns.
Dr. Reddy's Reports Mixed Q2 Results with Growth - 05 Nov, 2024
Dr. Reddy's Laboratories experienced a 15% drop in net profit to ₹1,255 crore, despite a 17% revenue increase to ₹8,016 crore. The company is expanding its GLP-1 drug portfolio and investing in R&D, aiming for a key biosimilar launch in 2027.
Dr Reddy's Faces Recall and Mixed Earnings Outlook - 04 Nov, 2024
Dr Reddy's Laboratories is recalling over 331,000 bottles of Cinacalcet due to manufacturing issues. Analysts predict a 12% revenue growth but a 7% profit decline for Q2FY25, indicating pressure on margins despite strong performance in the Indian market and Revlimid contributions.
Dr. Reddy's Recalls Cinacalcet Tablets in US - 03 Nov, 2024
Dr. Reddy's Laboratories announced a recall of over 3.3 lakh bottles of Cinacalcet tablets in the US due to manufacturing violations, including impurities exceeding FDA limits. The recall, initiated on October 9, 2024, is classified as Class II by the USFDA, indicating potential temporary health risks.
Dr Reddy's Q2 Preview: Profit Pressure Amid Stable Sales - 31 Oct, 2024
Dr Reddy's Laboratories anticipates a decline in Q2 net profit to Rs 1,397 crore due to margin pressures, despite a 12% revenue growth to Rs 7,694 crore. Stable US sales, driven by Revlimid, and strong domestic growth are positive factors, but operational performance is expected to suffer. Analysts will monitor drug approvals and margin outlook.
Dr Reddy's Launches New Drug Amid Stock Decline - 29 Oct, 2024
Dr Reddy's Laboratories launched Elobixibat, a drug for chronic constipation, under the brand name BixiBat. However, shares declined over 2.50% due to a stock split.
Dr. Reddy's Launches New Drug and Stock Split - 28 Oct, 2024
Dr. Reddy's Laboratories announced a 1:5 stock split, with shares rising 2%. The company launched Elobixibat, a breakthrough drug for chronic constipation, enhancing treatment options.
Dr. Reddy's Stock Split and Employer Recognition - 26 Oct, 2024
Dr. Reddy's Laboratories has been recognized as a top global pharma employer, ranking 15th, and will execute a stock split from ₹5 to Re 1 on October 28.
Insights on Dr Reddys Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 10.05% to 10.86% in Sep 2024 quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, DRREDDY stock has moved up by 1.8%
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 7.31K Cr → 8.35K Cr (in ₹), with an average increase of 6.4% per quarter
NEGATIVE IMPACTPromoter Holding Down
Promoters have decreased holdings from 26.65% to 26.64% in Sep 2024 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 1.39K Cr → 1.25K Cr (in ₹), with an average decrease of 9.8% per quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 27.68% to 27.53% in Sep 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 10.19% to 9.97% in Sep 2024 quarter
News
Mahayuti alliance breaches majority mark in Maharashtra, netizens share memes; say ‘Resort owners watching…’
Maharashtra election results 2024: According to the Election Commission of India website at 2 pm, BJP is leading in 123 seats, with its ally Shiv Sena at 55 and National Congress Party at 36 seats.23 Nov, 2024 02:25 PMMaharashtra CM Eknath Shinde lauds Ladki Bahin scheme for Mahayuti win. What is it?
As Maharashtra Chief Minister Eknath Shinde thanked the ‘ladki bahins’ for the Mahayuti alliance’s win in the 2024 Maharashtra Assembly Elections, we look at what the Ladki Bahin scheme is and who qua23 Nov, 2024 04:22 PMDiljit Dosanjh hits back amid controversy over reference to alcohol in songs: ‘For your kind info sir…’ | Watch video
Diljit Dosanjh’s Dil-Luminati Tour is a hit in India, despite media scrutiny over alcohol and violence in his songs. He addressed criticism during a Lucknow concert, challenging state censorship and d23 Nov, 2024 05:04 PMDr Reddys Laboratories Ltd Financials
Index Inclusions
Dr Reddys Laboratories Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 26.64% | ||
| Foreign Institutions | 27.53% | ||
| Mutual Funds | 10.86% | 8.06 | |
| Retail Investors | 9.97% | ||
| Others | 24.99% |
Dr Reddys Laboratories Ltd Key Indicators
Dr Reddys Laboratories Ltd Valuation
Dr Reddys Laboratories Ltd in the last 5 years
Lowest (3.37x)
October 27, 2019
Today (18.94x)
November 22, 2024
Industry (54.77x)
November 22, 2024
Highest (53.88x)
December 18, 2020
Dr Reddys Laboratories Ltd Earnings and Dividends
Dr Reddys Laboratories Ltd Earnings Results
Dr Reddys Laboratories Ltd’s net profit fell -15.28% since last year same period to ₹1,255.70Cr in the Q2 2024-2025. On a quarterly growth basis, Dr Reddys Laboratories Ltd has generated -9.82% fall in its net profits since last 3-months.
Read More about Earnings ResultsDr Reddys Laboratories Ltd Dividends May,2024
In the quarter ending March 2024, Dr Reddys Laboratories Ltd has declared dividend of ₹40 - translating a dividend yield of 6.59%.
Read More about Dividends
Dr Reddys Laboratories Ltd Technicals Summary
Bearish
Neutral
Bullish
Dr Reddys Laboratories Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Dr Reddys Laboratories Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Dr Reddys Laboratories Ltd shares.
Dr Reddys Laboratories Ltd (DRREDDY) share price today is ₹1214.45
Dr Reddys Laboratories Ltd is listed on NSE
Dr Reddys Laboratories Ltd is listed on BSE
- Today’s highest price of Dr Reddys Laboratories Ltd is ₹1223.2.
- Today’s lowest price of Dr Reddys Laboratories Ltd is ₹1193.6.
PE Ratio of Dr Reddys Laboratories Ltd is 18.94
PE ratio = Dr Reddys Laboratories Ltd Market price per share / Dr Reddys Laboratories Ltd Earnings per share
Today’s traded volume of Dr Reddys Laboratories Ltd(DRREDDY) is 7.64L.
Today’s market capitalisation of Dr Reddys Laboratories Ltd(DRREDDY) is ₹99738.18Cr.
| Dr Reddys Laboratories Ltd(DRREDDY | Price |
|---|---|
52 Week High | ₹1421.49 |
52 Week Low | ₹1074 |
Dr Reddys Laboratories Ltd(DRREDDY) share price is ₹1214.45. It is down -14.56% from its 52 Week High price of ₹1421.49
Dr Reddys Laboratories Ltd(DRREDDY) share price is ₹1214.45. It is up 13.08% from its 52 Week Low price of ₹1074
| Dr Reddys Laboratories Ltd(DRREDDY | Returns |
|---|---|
1 Day Returns | 19.1% |
1 Month Returns | -8.11% |
3 Month Returns | -12.69% |
1 Year Returns | 7.58% |